![](https://endpts.com/wp-content/uploads/2024/07/Laurent-Fischer-Adverum-feature.jpg)
Laurent Fischer, Adverum Biotechnologies CEO
Adverum prepares pivotal study for wet AMD gene therapy, touts Phase 2 data
Adverum Biotechnologies’ eye disease gene therapy has traversed a rocky road of safety troubles, but the company — presenting new Phase 2 data in wet AMD …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.